Display options
Cite
Singh AK, Jain S, Kumar D, et al. Antimicrobial susceptibility pattern of extended-spectrum beta- lactamase producing Klebsiella pneumoniae clinical isolates in an Indian tertiary hospital. J Res Pharm Pract. 2015;4(3):153-9doi: 10.4103/2279-042X.162363.
Singh, A. K., Jain, S., Kumar, D., Singh, R. P., & Bhatt, H. (2015). Antimicrobial susceptibility pattern of extended-spectrum beta- lactamase producing Klebsiella pneumoniae clinical isolates in an Indian tertiary hospital. Journal of research in pharmacy practice, 4(3), 153-9. https://doi.org/10.4103/2279-042X.162363
Singh, Amit Kumar, et al. "Antimicrobial susceptibility pattern of extended-spectrum beta- lactamase producing Klebsiella pneumoniae clinical isolates in an Indian tertiary hospital." Journal of research in pharmacy practice vol. 4,3 (2015): 153-9. doi: https://doi.org/10.4103/2279-042X.162363
Singh AK, Jain S, Kumar D, Singh RP, Bhatt H. Antimicrobial susceptibility pattern of extended-spectrum beta- lactamase producing Klebsiella pneumoniae clinical isolates in an Indian tertiary hospital. J Res Pharm Pract. 2015 Jul-Sep;4(3):153-9. doi: 10.4103/2279-042X.162363. PMID: 26312255; PMCID: PMC4548435.
Copy Download .nbib Format: NLM
Share it on

J Res Pharm Pract. 2015 Jul-Sep;4(3):153-9. doi: 10.4103/2279-042X.162363.

Antimicrobial susceptibility pattern of extended-spectrum beta- lactamase producing Klebsiella pneumoniae clinical isolates in an Indian tertiary hospital.

Journal of research in pharmacy practice

Amit Kumar Singh, Sonali Jain, Dinesh Kumar, Ravinder Pal Singh, Hitesh Bhatt

Affiliations

  1. Department of Microbiology, Mayo Institute of Medical Sciences, Barabanki, Uttar Pradesh, India.
  2. Department of Microbiology, Gold Field Institute of Medical Sciences and Research, Faridabad, Haryana, India.

PMID: 26312255 PMCID: PMC4548435 DOI: 10.4103/2279-042X.162363

Abstract

OBJECTIVE: There is an increased prevalence of extended-spectrum beta-lactamase producing Klebsiella pneumoniae (ESBL-KP) worldwide including India, which is a major concern for the clinicians, especially in intensive care units and pediatric patients. This study aims to determine the prevalence of ESBL-KP and antimicrobial sensitivity profile to plan a proper hospital infection control program to prevent the spread of resistant strains.

METHODS: KP isolates obtained from various clinical samples were evaluated to detect the production of ESBL by phenotypic methods. Antimicrobial susceptibility profile was also determined of all the isolates.

FINDINGS: Of 223 nonduplicate isolates of K. pneumoniae, 114 (51.1%) were ESBL producer and antimicrobial susceptibility profile showed the isolates were uniformly sensitive to imipenem and highly susceptible to beta-lactamase inhibitor combination drugs (67-81%) and aminoglycosides (62-76%), but less susceptible to third generation cephalosporins (14-24%) and non-β-lactam antibiotics such as nitrofurantoin (57%), fluoroquinolones (29-57%), piperacillin (19-23%), and aztreonam (15-24%).

CONCLUSION: This study found that beta-lactamase inhibitor combinations are effective in treatment of such infections due to ESBL-KP thus these drugs should be a part of the empirical therapy and carbapenems should be used when the antimicrobial susceptibility tests report resistance against inhibitors combinations.

Keywords: Beta-lactamase inhibitor; Klebsiella pneumoniae; extended-spectrum beta-lactamase; susceptibility pattern

References

  1. APMIS. 2000 Mar;108(3):237-40 - PubMed
  2. Indian J Med Microbiol. 2005 Jan;23(1):20-3 - PubMed
  3. Diagn Microbiol Infect Dis. 2005 Dec;53(4):257-64 - PubMed
  4. Indian J Med Microbiol. 2006 Apr;24(2):117-20 - PubMed
  5. J Microbiol Immunol Infect. 2007 Jun;40(3):248-54 - PubMed
  6. Indian J Med Microbiol. 2004 Jul-Sep;22(3):172-4 - PubMed
  7. Indian J Med Res. 2007 Nov;126(5):486-7 - PubMed
  8. Indian J Pathol Microbiol. 2008 Jan-Mar;51(1):139-42 - PubMed
  9. Infect Control Hosp Epidemiol. 2008 Nov;29(11):996-1011 - PubMed
  10. Indian J Med Res. 2009 Jun;129(6):695-700 - PubMed
  11. Antimicrob Agents Chemother. 2010 Mar;54(3):969-76 - PubMed
  12. BMC Microbiol. 2010 Jan 28;10:27 - PubMed
  13. N Engl J Med. 2010 May 13;362(19):1804-13 - PubMed
  14. Yonsei Med J. 2010 Sep;51(5):768-74 - PubMed
  15. J Infect Dev Ctries. 2010 Nov 24;4(11):717-22 - PubMed
  16. J Assoc Physicians India. 2010 Dec;58 Suppl:13-7 - PubMed
  17. Clin Microbiol Infect. 2011 Dec;17(12):1798-803 - PubMed
  18. Braz J Infect Dis. 2011 Nov-Dec;15(6):594-8 - PubMed
  19. Antimicrob Agents Chemother. 2012 Sep;56(9):4765-70 - PubMed
  20. ISRN Microbiol. 2011 Dec 01;2011:318348 - PubMed
  21. Ann Intensive Care. 2013 Jul 01;3(1):18 - PubMed
  22. J Infect Dev Ctries. 2014 Sep 12;8(9):1129-36 - PubMed
  23. EXCLI J. 2012 Jul 06;11:363-72 - PubMed

Publication Types